Order by 2pm for same-day dispatch. Free Royal Mail Tracked 24 over £24.95. Pay by card, Apple Pay, Google Pay or Pay by Bank. For in vitro laboratory research only.

BPC-157 vs TB-500

bpc vs tb500 infographic

BPC-157 and TB-500 are structurally distinct research peptides with different molecular targets and experimental literature. This comparison focuses on their origins, biochemical mechanisms and the types of cellular pathways examined in published research, rather than on selecting either compound for personal or therapeutic use.

BPC-157 vs TB-500 at a glance

Property BPC-157 TB-500
Type Synthetic pentadecapeptide (15 aa) Synthetic fragment of Thymosin β-4 (8 aa)
Origin Synthetic 15-aa peptide based on a gastric-protein sequence Actin-binding region derived from thymosin beta-4
Primary mechanism Angiogenesis, cytoprotection, nitric oxide Actin sequestration
Experimental pathway Endothelial / nitric-oxide-associated signalling Actin-associated cytoskeletal dynamics
Molecular weight 1419.53 g/mol 889.04 g/mol

Different origins

BPC-157 is a synthetic 15-amino-acid peptide based on a sequence identified within a gastric protein. TB-500 is a synthetic peptide derived from the actin-binding region of thymosin beta-4.

Their different structures and origins are relevant because the published literature examines different molecular pathways for each compound.

Different mechanisms

BPC-157: endothelial and nitric-oxide-associated signalling

BPC-157 literature includes VEGF/VEGFR2-associated signalling, nitric-oxide pathways, FAK-paxillin signalling and cellular-stress or gastrointestinal experimental systems.

TB-500: actin-associated cytoskeletal dynamics

TB-500 literature centres on G-actin binding, cytoskeletal organisation, cellular migration and endothelial-response endpoints.

Distinct experimental targets

The mechanisms described in the literature are different, so comparative studies should define the endpoint being measured rather than treating one peptide as a substitute for the other.

Why compare the pathways in the same experimental system?

BPC-157 and TB-500 act through different molecular systems, which makes them useful for comparative or multi-factor experimental designs. BPC-157 literature includes endothelial and nitric-oxide-associated signalling, while TB-500 literature centres on actin-associated cytoskeletal organisation and cellular migration.

Research involving both compounds should measure the combined system directly rather than assuming additive effects from the individual literatures.

Further reading

For full mechanistic overviews, see the BPC-157 research guide and TB-500 research guide. For a formulation-level comparison of compounds that include these peptides, see the KLOW Blend component breakdown.


Research use only. This article is provided for laboratory and scientific reference purposes. Trutide research products are supplied strictly for in vitro laboratory research and are not for human or veterinary use, clinical use, self-administration, diagnosis, treatment or prevention of disease.

References

  1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. doi:10.2174/138161211796196954
  2. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
  3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793
  4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin β4 defined by active sites in short peptide sequences. The FASEB Journal. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
  5. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and standard angiogenic growth factors. Current Pharmaceutical Design. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447

Last updated: 20 June 2026

The research list

Batch alerts. New compounds. Research updates.

Be first to hear when a new batch lands.